- The document is a presentation from Quintiles given at the Barclays Global Healthcare Conference on March 10, 2015. - It contains forward-looking statements and discusses the use of non-GAAP financial measures to provide supplemental information to management and investors. - The presentation provides an overview of Quintiles' vision, strategic agenda, track record of growth, financial highlights from 2014, the product development and integrated healthcare services market opportunities, and what makes Quintiles differentiated in the industry.

1. © Copyright 2014 Quintiles
Barclays
Global Healthcare Conference
March 10, 2015
NYSE: Q

2. 2
Forward Looking Statements and
Use of Non-GAAP Financial Measures
This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements reflect,
among other things, the Company’s current expectations and anticipated results of operations, all of which are subject to
known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements,
market trends or industry results to differ materially from those expressed or implied by such forward-looking statements.
Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements
and should be evaluated as such. Without limiting the foregoing, the words “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “may,” “plans,” “projects,” “should,” “guidance,” “targets,” “will” and the negative thereof and similar words and
expressions are intended to identify forward-looking statements. Actual results may differ materially from the Company’s
expectations due to a number of factors, including that most of the Company’s contracts may be terminated on short notice,
the Company may be unable to maintain large customer contracts or to enter into new contracts, the Company may under-
price its contracts, overrun its cost estimates, or fail to receive approval for or experience delays in documenting change
orders, the historical indications of the relationship of backlog to revenues may not be indicative of their future relationship,
the Company is subject to the complex and changing regulatory and international environments in which the Company
operates, the Company may be unable to successfully identify, acquire and integrate businesses, the Company’s
substantial indebtedness, and other risks more fully set forth in the Company's filings with the SEC, including the
Company’s annual report on Form 10-K for the fiscal year ended December 31, 2014, filed with the SEC on February 12,
2015, as such factors may be amended or updated from time to time in the Company’s periodic filings with the SEC, which
are accessible on the SEC's website at www.sec.gov. The Company assumes no obligation to update any forward-looking
statement after the date of this presentation, whether as a result of new information, future developments or otherwise.
This presentation includes financial measures not prepared in accordance with accounting principles generally accepted in
the United States (“GAAP”). Management believes that these non-GAAP financial measures provide useful supplemental
information to management and investors regarding the underlying performance of the Company’s business operations and
are more indicative of core operating results as they exclude certain items whose fluctuations from period-to-period do not
necessarily correspond to changes in the core operations of the Company’s business. Investors and potential investors are
encouraged to review the reconciliations of the non-GAAP financial measures to their most directly comparable GAAP
measures attached to this presentation.

3. 3
Enterprise Vision and Strategy
Quintiles
Vision
We bring people and knowledge
together for a healthier world.
Our Customer Promise
Excellence at
Global People,
Process &
Technology
Scientific,
Therapeutic &
Rx Experience
Quantitative
& Analytical
Expertise
Biopharma
Product
Development
Integrated
Healthcare
Services

4. 4
Strategic Agenda
• Profitable growth at above market rates
• Investments leveraging our scale
• World class customer relationship management
• Productivity, delivery & quality
• Top leadership and people development
Connecting insights with superior
delivery for better outcomes

5. 5
$463
$490
$544
$612
$720
0
100
200
300
400
500
600
700
800
2010 2011 2012 2013 2014
$2,997
$3,295
$3,692
$3,808
$4,166
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
2010 2011 2012 2013 2014
$3,552
$4,044
$4,501
$4,899
$5,602
1.19x 1.23x 1.22x
1.29x
1.34x
0.00x
0.50x
1.00x
1.50x
2.00x
0
1,000
2,000
3,000
4,000
5,000
6,000
2010 2011 2012 2013 2014
$7,115
$7,973
$8,705
$9,855
$11,244
0
2,000
4,000
6,000
8,000
10,000
12,000
2010 2011 2012 2013 2014
Track Record of Profitable Growth and Consistency
Backlog
(1) Book-to-bill calculated as NNB divided by Adjusted Service Revenues
Adjusted Service Revenues
’10 – ’14 CAGR = 8.6%
Adjusted EBITDA
’10 – ’14 CAGR = 11.7%
Net New Business and Book-to-Bill(1)
’10 – ’14 CAGR = 12.1%
$Millions
$Millions
$Millions
$Millions
15.4% 14.9% 14.7% 16.1% 17.3%Margin
Long term performance underpinned with a diversified customer portfolio
(5)

6. 6
2014 Financial Highlights
(1) See appendix slide 25
(2) See appendix slide 24
Financial highlights Other highlights
10.1% Constant Currency Revenue(1)
6.3% in Product Development
22.5% in IHS
1.34x Book-to-bill ratio
1.41x in Product Development
1.15x in IHS
120 bps Adjusted Income from
Operations margin(2) expansion
$11.2bn Consolidated Backlog
14.4% Net new business growth
33.9% Adjusted Net Income growth $867mm Cash and cash equivalents
31.1% Diluted Adjusted EPS growth $415mm Share Repurchases
IHS Integrated Healthcare Services

7. 7
Attractive and growing market
~$200bn total market across both segments with increasing outsourcing penetration
which drives estimated growth of 6% – 8% per year from 2014 – 2017
$95bn Product Development
Market(1)
$98bn Integrated Healthcare Services
Market(1,2)
Phase I-IV Clinical Development
$95bn
Outsourced
$21bn
Addressable
$52bn
Integrated Healthcare Services
$98bn
Outsourced
$22bn
(1) Based on Company estimates
(2) Includes market access, reimbursement, observational studies, comparative
effectiveness research, health economics & outcomes research, and commercial consulting
(3) For the year ended 12/31/14
Product Development Services
(~74% of Revenues) (3)
Integrated Healthcare Services (‘IHS’)
(~26% of Revenues) (3)
Approval
Phase I Phase II Phase III Healthcare DeliveryCommercialPhase
IV

8. 8
Increase R&D
productivity
Simplify the
complex –
Provide global
scientific
expertise
Improve
investigator &
patient access
Increasing
importance of
providers &
patients
Using real-
world data &
analytics to
drive decision
making
Increasing
demand for
evidence &
market access
Market drivers
We understand the needs of biopharma and how the industry is evolving

9. 9
Product Development
• Core segment representing 74% of Consolidated
Service Revenues and 91% of Segment Income from
Operations(1)
• Market leader in Product Development services
› #1 in Clinical Development / #2 in Central Lab
• Diversified customer portfolio across
biopharma segments with tailored segment solutions
• Integrated offerings
• Proactive Business Development
› 1.41(1) book-to-bill ratio
› Strong RFP volumes
› Evolution of integrated end to end partnership models
› Strong wins across large, mid-size and emerging
biopharma
Ph - I Ph - II Ph - III Ph-IIIB & IV
Product Development Services
Technology and informatics
Deep science, therapeutic, &
regulatory expertise
Globally harmonized best in
class processes
Novel approaches to
development
Global workforce
(1) For the year ended 12/31/14
Improving the probability of success using science, technology and global delivery

10. 10
Integrated Healthcare Services
• IHS segment represents 26% of Consolidated Service
Revenues and 9% of Segment Income from Operations(1)
• IHS includes market leading solutions
› One of the leading outsourced global contract
pharmaceutical sales organization
› One of the leading observational services organizations
• Convergence within healthcare
› Solutions aligned to capitalize on evolving convergence
of patient, payer and provider, and to leverage evidence
-based insights into commercial strategies to provide an
integrated approach
• Thought leadership in consulting and
observational research
• Book-to-bill of 1.15(1)
Integrated Healthcare
Services Offerings
Commercial Services:
• Contract Sales
• Market Entry / Market Exit
• Integrated Channel Management
• Patient Engagement Services
• Market Access &
Commercialization Consulting
Communications &
Engagement Services:
• Digital Patient Services
• Brand & Scientific Communications
Real-World and Late Phase
Research:
• Observational Studies
• Product and Disease Registries
• Comparative Effectiveness Studies
Other Healthcare Solutions
• Encore
Integrated Healthcare Services
Phase II & III Commercial Healthcare Delivery
(1) For the year ended 12/31/14
Improving the probability of commercial success

11. 11
The Quintiles Difference
Deep science, therapeutic,
& regulatory expertise
Global harmonized
best in class
processes & workforce
Technology & informatics
Infosario Platform
Planning & Design
Global Safety System
Analytics & Informatics
Genomics & Biomarkers
Digital Patient Communities
Clinicalresearch.com
Mediguard.com
“I Am More Than Lupus”
61mm
Unique Patient Records (EHR)
~1,300
Prime & partner sites
~250,000
Investigators
Enabled by a global delivery
network of 4,000 Professionals
100
countries serviced
+110
Risk Based Monitoring Studies
(RBM) – Leader in RBM
950
Medical doctors
1,000
PhDs
13
Therapeutic centers of excellence
~800
Statisticians & statistical
programmers
~5,700
Protocols, since 2000
Infosario Platform
Infosario Outcome System 3.0
430
Direct-to-Patient projects
relying on technology
100%
Compliance trained field resources
>220
Product launches in 20 countries
in last 5 years
>5,600
Sites active in observational research
7,100
Sales representatives
~770
Clinical educators
14,500
Tracked HTA reports from 100
agencies
The integration of our assets creates differentiated value

12. 12
Deep customer relationships
Largest backlog in industry with diversification and sustainability
Helped develop or commercialize 100% of the Top 100 best-selling products
Worked with all top 20 biopharma companies in each of last 12 years
11 customer accounts generated $100mm+ of net new business(1)
14 customers with 100mm+ service revenues(1)
~62% of service revenues outside of U.S.
< 10% of revenues from largest customer – diverse customer base
C-Level access and relationships: >550 biopharma customers
Transactional Services Partnered Services End-to-End Partnership Solutions
(1) As of 12/31/14

13. 13
Industry leading data and technology capabilities
The Quintiles Difference
Infosario
Analytics
Patient and Provider
Engagement Tools
Systems
Infosario™ Platforms
Technology Solutions
as a Service
• Systems & Data Integrator
• Platform Hosting
Planning & Design Post Marketing Approval
• Planning and Design
• Investigator Site Gateway
• Risk Based Monitoring
• Clinical Trial Management
• eDetailing
• Safety Management
• Late Phase Registry
Infosario® Engagement:
• Mediguard.org
• ClinicalResearch.com
• Customized communities

14. 14
Recognized for excellence
Differentiated through innovation, thought leadership and talent
Industry Leader in Phase
II/III Research

15. 15
Quintiles
Differentiated market leader
Market leader in Product
Development services
Deep and diverse customer
relationships
Serve an attractive and
growing market
Geographically diversified
revenue base
Strong free
cash flow
First mover advantage with
Clinical Development
Informatics technology
Largest backlog in industry
Best in industry
operating margins
Consistent long term
financial
performance

16. 16
Appendix

17. 17
Adjusted Service Revenues Reconciliation
Adjusted Service Revenues
Reconciliation
Year Ended December 31
(In Thousands) 2014 2013 2012 2011 2010
Non-GAAP Adjusted Service Revenues:
GAAP Service Revenues as Reported 4,165,822 $3,808,340 $3,692,298 $3,294,966 $3,060,950
Deconsolidation of PharmaBio – – – – (64,198)
Adjusted Service Revenues $4,165,822 $3,808,340 $3,692,298 $3,294,966 $2,996,752

18. 18
Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation
Year Ended December 31
(In Thousands) 2014 2013 2012 2011 2010
Non-GAAP Adjusted EBITDA:
Net Income Attributable to Quintiles Transnational Holdings Inc. $356,383 $226,591 $177,546 $241,772 $160,596
Net income (loss) attributable to noncontrolling interests 118 (564) (915) (1,445) 4.659
Interest Expense, Net 97,179 119,571 131,304 105,126 137,631
Income Tax Expense 150,056 95,965 93,364 15,105 77,582
Depreciation and Amortization 121,013 107,504 98,288 92,004 84,217
Restructuring Costs 8,988 14,071 18,741 22,116 22,928
Impairment Charges – – – 12,295 2,844
Incremental Share-based Compensation Expense – – 13,637 2,553 –
Bonus Paid to Certain Holders of Stock Options – – 11,308 10,992 –
Management Fees – 27,694 5,309 5,213 5,159
Loss on Extinguishment of Debt – 19,831 1,275 46,377 –
Other (Income) Expense, Net (8,978) (185) (3,572) 9,073 15,647
Equity in Losses (Earnings) from Unconsolidated Affiliates (4,368) 1,124 (2,567) (70,757) (1,110)
Deconsolidation of PharmaBio – – – – (47,393)
Adjusted EBITDA $720,391 $611,602 $543,718 $490,424 $462,760
% of Adjusted Service Revenues 17.3% 16.1% 14.7% 14.9% 15.4%

19. 19
Adjusted Net Income Reconciliation
Adjusted Net Income Reconciliation
Year Ended December 31
(In Thousands) 2014 2013 2012 2011 2010
Non-GAAP Adjusted Net Income:
Net income attributable to Quintiles Transnational Holdings Inc. $356,383 $226,591 $177,546 $241,772 $160,596
Restructuring Costs 8,988 14,071 18,741 22,116 22,928
Impairment Charges – – – 12,295 2,844
Incremental Share-based Compensation Expense – – 13,637 2,553 –
Bonus Paid to Certain Holders of Stock Options – – 11,308 10,992 –
Management Fees – 27,694 5,309 5,213 5,159
Loss on Extinguishment of Debt – 19,831 1,275 46,377 –
Interest Rate Swap Termination Fee – – – 11,630 –
Gain on Sale of Business Assets – – – (74,880) –
Deconsolidation of PharmaBio – – – – (28,979)
Adjustment to Estimated Contingent Consideration (8.839) (4,910) (4,922) – –
Tax Effect of Non-GAAP Adjustments (3,114) (22,304) (18,885) (21,063) (752)
Other Income tax Adjustments – 3,057 – (66,000) –
Adjusted Net Income $353,418 $264,030 $204,009 $191,005 $161,796
% of Adjusted Service Revenues 8.5% 6.9% 5.5% 5.8% 5.4%

20. 20
1 Change in estimated fair value of contingent consideration on business combinations.
2Represents the Company’s change in its permanent reinvestment assertion during 2Q 2013 retroactively applied to 1Q 2013 for the new estimated annual
effective income tax rate for 2013.
Note: Totals may not sum due to rounding; percentages are calculated from the actual results rounded to the nearest thousand.
Income Statement
GAAP – Non-GAAP Reconciliation
Three Months Ended December 31
(millions of dollars)
Selling,
General and
Administrative
Income
from
Operations
Net Income
Attributable
to Quintiles
Selling,
General and
Administrative
Income
from
Operations
Net Income
Attributable
to Quintiles
As Reported $ 225.1 $ 158.9 $ 88.4 $ 232.8 $ 127.0 $ 73.0
Adjustments
Restructuring Costs - 5.2 5.2 - 2.2 2.2
Tax Effect of Adjustments - - (1.8) - - (2.0)
Adjustment to Estimated Contingent Consideration1
- - - - - (3.5)
Loss on Extinguishment of Debt - - - - - 3.3
Adjusted Non-GAAP Basis $225.1 $164.2 $91.8 $232.8 $129.2 $73.0
% of Service Revenues 21.2% 15.4% 8.6% 23.2% 12.9% 7.3%
2014 2013
Year Ended December 31
(millions of dollars)
Selling,
General and
Administrative
Income
from
Operations
Net Income
Attributable
to Quintiles
Selling,
General and
Administrative
Income
from
Operations
Net Income
Attributable
to Quintiles
As Reported $ 882.3 $ 590.4 $ 356.4 $ 860.5 $ 462.3 $ 226.6
Adjustments
Restructuring Costs - 9.0 9.0 - 14.1 14.1
Adjustment to Estimated Contingent Consideration1
- - (8.8) - - (4.9)
Tax Effect of Adjustments - - (3.1) - - (22.3)
Management Fees - - - (27.7) 27.7 27.7
Loss on Extinguishment of Debt - - - - - 19.8
Other Income Tax Adjusments2
- - - - - 3.0
Adjusted Non-GAAP Basis $882.3 $599.4 $353.4 $832.8 $504.1 $264.0
% of Service Revenues 21.2% 14.4% 8.5% 21.9% 13.2% 6.9%
2014 2013

21. 21
Constant Currency Reconciliation
Service Revenues and Income from Operations
The exchange rate impacts on service revenues equals the current period service revenues at actual rates less the current period service revenues for foreign currency denominated
contracts recalculated at the prior period exchange rates. The exchange rate impacts on expenses equals the current period expenses at actual rates less the current period expenses
recalculated at the prior period exchange rates.
The segment detail presented above excludes general corporate and unallocated expenses and restructuring costs.
(millions of dollars)
Consolidated Actual
Exchange
Impact Constant Actual
Exchange
Impact Constant
Service Revenues 1,064.0$ (33.4)$ 1,097.4$ 6.0% (3.3%) 9.3%
Income from Operations 158.9$ 5.6$ 153.3$ 25.1% 4.4% 20.7%
Adjusted Income from Operations 164.2$ 5.4$ 158.8$ 27.1% 4.2% 22.9%
Adjusted Income from Operations Margin 15.4% 14.5%
Product Development
Service Revenues 774.4$ (18.6)$ 793.0$ (0.1%) (2.4%) 2.3%
Income from Operations 168.0$ 6.6$ 161.4$ 9.9% 4.3% 5.6%
Income from Operations Margin 21.7% 20.4%
Integrated Healthcare Services
Service Revenues 289.6$ (14.8)$ 304.4$ 26.5% (6.5%) 33.0%
Income from Operations 24.3$ (1.4)$ 25.7$ 107.2% (12.3%) 119.5%
Income from Operations Margin 8.4% 8.4%
Three Months Ended December 31 Year on Year Growth
(millions of dollars)
Consolidated Actual
Exchange
Impact Constant Actual
Exchange
Impact Constant
Service Revenues 4,165.8$ (25.7)$ 4,191.5$ 9.4% (0.7%) 10.1%
Income from Operations 590.4$ 22.8$ 567.6$ 27.7% 4.9% 22.8%
Adjusted Income from Operations 599.4$ 22.6$ 576.8$ 18.9% 4.5% 14.4%
Adjusted Income from Operations Margin 14.4% 13.8%
Product Development
Service Revenues 3,097.8$ (5.1)$ 3,102.9$ 6.1% (0.2%) 6.3%
Income from Operations 645.2$ 27.3$ 617.9$ 14.8% 4.9% 9.9%
Income from Operations Margin 20.8% 19.9%
Integrated Healthcare Services
Service Revenues 1,068.0$ (20.6)$ 1,088.6$ 20.2% (2.3%) 22.5%
Income from Operations 64.8$ (4.8)$ 69.6$ 53.8% (11.3%) 65.1%
Income from Operations Margin 6.1% 6.4%
Year on Year GrowthYear Ended December 31

22. 22
1 Other includes a mix of more than 40 currencies.
Contractual Revenue Currency Mix
and Foreign Exchange Analysis
USD Sterling Euro Yen Other
1
Total
4Q '14 $685.1 $77.5 $157.9 $103.8 $39.7 $1,064.0
% of total 64% 7% 15% 10% 4% 100%
4Q '13 $587.4 $71.1 $207.2 $108.3 $29.9 $1,003.9
% of total 59% 7% 21% 11% 2% 100%
4Q '14 Average Rate $1.58 $1.25 ¥114.53
4Q '13 Average Rate $1.62 $1.36 ¥100.45
% Increase (Decrease) (2.2%) (8.3%) (12.3%)
Consolidated Service Revenues (millions of dollars)
USD Sterling Euro Yen Other
1
Total
YTD 2014 $2,592.9 $331.8 $684.8 $424.5 $131.8 $4,165.8
% of total 63% 8% 16% 10% 3% 100%
YTD 2013 $2,367.7 $285.2 $678.3 $381.4 $95.7 $3,808.3
% of total 62% 7% 18% 10% 3% 100%
YTD '14 Average Rate $1.65 $1.33 ¥105.85
YTD '13 Average Rate $1.56 $1.33 ¥97.59
% Increase (Decrease) 5.3% 0.0% (7.8%)
Consolidated Service Revenues (millions of dollars)